Cognition Therapeutics, Inc. Common Stock
CGTXCognition Therapeutics, Inc. (CGTX) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer's disease. The company's approach involves targeting molecular pathways involved in neurodegeneration to develop disease-modifying treatments. Founded with a focus on translating scientific discoveries into innovative medicines, Cognition Therapeutics aims to address unmet medical needs in cognitive disorders.
Company News
Mesoblast Limited has appointed James M. O'Brien as its US-based Chief Financial Officer to support the company's transition to a fully integrated commercial organization, leveraging his extensive financial management experience in life sciences and biotechnology.
Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.
Cognition Therapeutics raised $30 million through a registered direct offering of 14.7 million common stock shares at $2.05 per share, with proceeds intended to support Phase 3 development of zervimesine for neurodegenerative disorders.
Cognition Therapeutics secured a securities purchase agreement to sell 14,700,000 shares, expecting gross proceeds of approximately $30 million. The funds will support Phase 3 programs for zervimesine in neurodegenerative disorders and general corporate purposes.
Cognition Therapeutics reported positive results from its Phase 2 studies of zervimesine (CT1812) in dementia with Lewy bodies (DLB) and Alzheimer's disease. The company plans to advance zervimesine into late-stage trials for these indications.
